Navigation Links
Micromet Key Events for 2009
Date:1/5/2009

tients with metastatic breast cancer. Micromet has licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203, which is being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis. Additional BiTE antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy and intended utilization of our product candidates and the development of our BiTE antibody technology. You are urged to consider statements that include the words "may," "potential," or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include the risk that product candidates that appeared promising in early research, preclinical studies or clinical trials do not demonstrate safety and/or efficacy in subsequent clinical trials, the risk that encouraging results from early research, preclinical studies or clinical trials may not be confirmed upon further analysis of the detailed results of such research, preclinical study or clinical trial, and th
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Expands Committed Equity Financing Facility to $75 Million
2. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
3. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
4. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
5. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
6. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
7. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
8. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
9. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
10. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
11. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  WaferGen Bio-systems, Inc. ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... expected to begin trading on The NASDAQ Stock Market ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
(Date:8/21/2014)... /CNW/ - Eisai Limited is pleased to support the Canadian ... book available in Canada . The comic ... educate children and their parents about epilepsy, the most common ... than 300,000 Canadians. Eisai is guided by a corporate philosophy ... the patient is central – there was a need within ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... , June 14 Upsher-Smith Laboratories, Inc. today ... for USL255 (extended-release topiramate), an internally developed program for the ... technology.  USL255 is designed to provide convenient once-daily dosing and ... topiramate options. , , ...
... /PRNewswire/ -- MedShape Solutions, Inc. was recently ... for their MORPHIX™ Suture Anchor at the recent Medical ... of jurors awarded the MORPHIX™ Anchor the Gold Award ... proprietary shape memory polymer, PEEK Altera™.  Previous winners of ...
Cached Medicine Technology:Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy 2Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy 3MedShape Solutions, Inc. Receives Industry Honors and Awards 2
(Date:8/23/2014)... 23, 2014 Professional kitchen employees, prospective ... aid in preparing for Food Safety Certification exams thanks ... by Dynamic Path. , Dynamic Path announced the release ... more than 200 review questions for culinary industry students ... to cover requirements of the ServSafe® Food Safety Certification, ...
(Date:8/23/2014)... TX (PRWEB) August 23, 2014 Youth ... of Texas. It’s no different in Houston, TX. Substance ... are falling victim to drug and alcohol dependency in ... are looking to beat substance abuse, but don’t know ... juvenile treatment facility can be a challenge because most ...
(Date:8/22/2014)... Search Engine Optimization is needed to bring a ... and get more audience and sales. Top 10 ... hosting suppliers and announced that HostGator.com ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... hosting suppliers for webmasters from the USA, UK, ... Linux hosting (including VPS and cloud hosting). , ...
(Date:8/22/2014)... 23, 2014 Recently, Skmen.com, an experienced ... of 2014 bohemian dresses in its online store. Moreover, ... prices, up to 28% off. All the international clients ... August 31, 2014. , The company’s professional online ... to show worldwide customers more the latest information about ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 ... that is written by marketing experts for marketers to ... links has caught the attention of Shane Michaels, prompting ... with Internet marketing in any way knows that content ... in the industry,” reports Michaels. “But even though content ...
Breaking Medicine News(10 mins):Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2Health News:Top10BestSEOHosting.com Announces Best Cheap Hosting Suppliers Of This Summer 2Health News:Cheap Bohemian Dresses Unveiled by Experienced Supplier Skmen.com 2Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2
... today (Oct. 31) announced that it is partnering with ... Medical School to administer a transformative $7.2 million project ... in Liberia, an African nation with which IU has ... the Center for Excellence in Health and Life Sciences ...
... to tackle hospital-acquired infections, such as C. difficile ... infections following specific surgical procedures. That is the key ... of the urology journal BJUI . UK ... a standard surgical procedure to diagnose prostate cancer developed ...
... Certain factors unique to professional sports can increase the risk ... staff, a new report suggests. Norovirus is the most ... and causes 21 million cases of illness in the United ... 31 online edition of the journal Clinical Infectious Diseases ...
... a 2010 outbreak involving several NBA teams, the ... a professional sports association. Published in Clinical ... ), the study highlights unique circumstances for spreading ... on and off the court. Norovirus ...
... 2011)In a technical tour de force, scientists at Fox ... of 178 candidate drugs capable of blocking the activity ... critical for cancer and other diseases. Additionally, a free ... to the research community. This unique library represents an ...
... , SUNDAY, Oct. 30 (HealthDay News) --,A physically active ... a new study. Glaucoma, a leading cause of blindness, ... damages the optic nerve. In this study, researchers looked ... 5,650 men and women aged 48 to 90 in Britain. ...
Cached Medicine News:Health News:$7.2 million project will address a national shortage of health-care workers in Liberia 2Health News:$7.2 million project will address a national shortage of health-care workers in Liberia 3Health News:$7.2 million project will address a national shortage of health-care workers in Liberia 4Health News:$7.2 million project will address a national shortage of health-care workers in Liberia 5Health News:Drugs used to tackle hospital-acquired infections can increase post-op complications 2Health News:Stomach Bug Easily Passed Among Pro Sports Teams: Report 2Health News:NBA players not immune to serious illness from norovirus 2Health News:First-of-its-kind study creates new tool for targeted cancer drug development 2Health News:First-of-its-kind study creates new tool for targeted cancer drug development 3Health News:Glaucoma Experts Eye Benefits of Exercise 2
... Provides a more occlusive wrap than ... where wound transudate must be contained. Predictable ... be inert, nonantigenic, and nonpyrogenic. ,VICRYL (polyglactin ... synthetic absorbable copolymer of glycolide and lactide, ...
Used for implantation to reinforce soft tissue. Supplied sterile in peel-open packages. Intended for one-time use....
... mesh onlays are pre-cut and pre-shaped to ... are more frequently done. These pre-shaped onlays ... ProLite Ultra and are designed for use ... in both small and large sizes, they ...
... such as laparoscopic inguinal hernia repair ... a surgical biomaterial that enables rapid ... provides the answer to the most ... Made from strong, soft, inert and ...
Medicine Products: